Question 1

Am I eligible for this trial based on my cancer type and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer clinical trial (NCT06989112). Contact the study team or your healthcare provider for specific answers.

Question 2

How does the experimental treatment compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer clinical trial (NCT06989112). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of the treatments being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer clinical trial (NCT06989112). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer clinical trial (NCT06989112). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer clinical trial (NCT06989112). Contact the study team or your healthcare provider for specific answers.

Question 6

Will my insurance cover the costs associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer clinical trial (NCT06989112). Contact the study team or your healthcare provider for specific answers.

What this study is about